C4 Therapeutics (CCCC) Research & Development (2019 - 2026)

C4 Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $24.6 million for Q1 2026.

• In Q1 2026, Research & Development fell 9.11% year-over-year to $24.6 million; the TTM figure through Mar 2026 stood at $101.8 million (down 11.64% YoY), while the FY2025 annual figure was $104.2 million, down 5.78% from the prior year.
• Research & Development for Q1 2026 stood at $24.6 million, down from $25.0 million in the prior quarter.
• The five-year high for Research & Development was $32.5 million in Q4 2024, with the low at $22.5 million in Q1 2024.
• The 5-year median for Research & Development is $28.3 million (2023), against an average of $27.9 million.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 34.51% in 2022, then fell 23.16% in 2025.
• C4 Therapeutics' Research & Development stood at $30.7 million in 2022, then declined by 0.85% to $30.4 million in 2023, then grew by 6.98% to $32.5 million in 2024, then dropped by 23.16% to $25.0 million in 2025, then decreased by 1.51% to $24.6 million in 2026.
• Business Quant data shows CCCC's Research & Development at $24.6 million in Q1 2026, $25.0 million in Q4 2025, and $26.0 million in Q3 2025.